Synthesis and Characterization of Deuterated Detomidine for Use in Equine Medication Regulation

Detomidine, 5-[(2,3-dimethylphenyl)methyl]-1H-imidazole, is a tranquilizer/sedative/analgesic widely used in equine medicine and regulated by several different analyte concentrations of detomidine and its hydroxydetomidine and carboxydetomidine metabolites in plasma and urine. Accurate regulatory quantitation of detomidine at low picogram/mL concentrations requires the availability of a stable isotope internal standard of detomidine; however, to the best of our knowledge, no certified deuterated internal standard of detomidine is commercially available and its synthesis has not been reported. Here, we report the first synthesis and characterization of detomidine-d, prepared in six sequential steps consisting of a deuterium-hydrogen exchange, diazotization, Grignard coupling, hydrogenolysis, and palladium-catalyzed deuterium-hydrogen exchange. This overall route gave detomidine-d in moderate chemical yield with each intermediate purified to > 90% purity as determined by RP-HPLC. Regiochemistry and isotopic enrichment were confirmed by ¹H NMR and LC/MS, demonstrating a viable method for the incorporation of three deuterium atoms into the detomidine scaffold. This internal standard will allow for precise LC/MS quantitation of detomidine at regulatory threshold concentrations, enabling accurate detection and quantitation of picogram/mL concentrations in equine blood and urine samples, thereby supporting regulatory compliance for equine medication control programs.